US Patent

US10940110 — Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations

Method of Use · Assigned to Sunovion Respiratory Development Inc · Expires 2029-02-26 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for improving lung function in chronic COPD by administering a muscarinic antagonist with a high efficiency nebulizer.

USPTO Abstract

A method is provided for improving lung function in COPD by administering a muscarinic antagonist with a high efficiency nebulizer.

Drugs covered by this patent

glycopyrrolate (Glycopyrrolate) · Yonsei University

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1773`	—	glycopyrrolate

Patent Metadata

Patent number: US10940110
Jurisdiction: US
Classification: Method of Use
Expires: 2029-02-26
Drug substance claim: No
Drug product claim: Yes
Assignee: Sunovion Respiratory Development Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.